In other studies, PHGDH enzyme augmentation was associated with resistance to a therapeutic agent in non-small cell lung cancer [14] (NSCLC) and in hepatocellular carcinoma (HCC) [16]. Here, PHGDH is linked to non-small cell lung carcinoma.